Enveric Biosciences
ENVB
21 hedge funds and large institutions have $1.99M invested in Enveric Biosciences in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 10 closing their positions.
300% more call options, than puts
Call options by funds: $12K | Put options by funds: $3K
0% less ownership
Funds ownership: 0% → 0% (-0%)
19% less funds holding
Funds holding: 26 → 21 (-5)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
45% less capital invested
Capital invested by funds: $3.61M → $1.99M (-$1.62M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$78.7K |
| 2 |
Millennium Management
New York
|
+$53.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.51K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.38K |
| 5 |
HF
HRT Financial
New York
|
+$4.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$213K |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$94K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$58K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$48.9K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$46.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citadel Advisors
Miami,
Florida
| – | -$12.8K | -6 | Closed |
|
|
BFM
27
Boothbay Fund Management
New York
| – | -$15K | -5 | Closed |
|
|
WAM
28
Warberg Asset Management
Winnetka,
Illinois
| – | -$15K | -5 | Closed |
|
29
Citigroup
New York
| – | -$6K | -2 | Closed |
|
|
IWC
30
Integrated Wealth Concepts
Waltham,
Massachusetts
| – | -$4K | -1 | Closed |
|
31
JP Morgan Chase
New York
| – | -$4K | -1 | Closed |
|
32
Osaic Holdings
Scottsdale,
Arizona
| – | -$1K | – | – |
|
ENVB Hedge Fund Activity: Q2 2022 in Review
21 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q2 2022, worth a combined $1.99M — down 45% from $3.61M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ENVB and 5 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was AdvisorShares Investments, adding an estimated $78.7K. The largest seller was Renaissance Technologies, cutting an estimated $213K.
- 21 institutional investors held Enveric Biosciences (ENVB) as of Q2 2022, down from 26 in Q1 2022.
- Funds reported $1.99M of Enveric Biosciences stock for Q2 2022, down 45% quarter-over-quarter.
- 5 funds opened new Enveric Biosciences positions in Q2 2022 and 10 closed out, a net change of -5 holders.
- The largest Enveric Biosciences buyer in Q2 2022 was AdvisorShares Investments, an estimated $78.7K added.
- The largest Enveric Biosciences seller in Q2 2022 was Renaissance Technologies, an estimated $213K sold.
Based on aggregated 13F filings for Q2 2022.